Skip to main content
SpringerLink
Log in

Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

We aimed to investigate the cisplatin-related hearing toxicity and its possible relationship with polymorphic variants in DNA repair genes, ERCC1, ERCC2, and XRCC1.

Methods

Fifty patients treated with cisplatin in the past were included in the study. There were 29 females and 21 males; mean age 13.4 ± 6.0 years). The polymorphism in DNA repair genes was studied using primer and probes in Light Cycler device after DNA isolation was carried out with PCR technique. The polymorphisms and clinical risk factors were evaluated using Chi square test and logistic regression modelling.

Results

The patients had hearing loss in 44%. For ERCC1 gene, the patients with hearing loss had 50% of GG (wild type), 40.9% of AG and 9.1% of AA genotypes, while the patients without hearing loss had 28.6% of GG, 53.5% of AG, and 17.9% of AA genotypes. For ERCC2 gene, the patients with hearing loss had 18.2% of GG (wild type), 40.9% of TG, and 40.9% of TT genotypes, while the patients without hearing loss had 10.7% of GG 39.3% of TG, and 50% of TT genotypes. For XRCC1 gene, the patients with hearing loss had 18.2% of CC (wild type), 59.1% of CT, and 22.7% of TT genotypes, while the patients without hearing loss had 35.7% of CC, 50% of CT, and 14.3% of TT genotypes. There was no statistically significant association among the groups (p = 0.24).

Conclusion

We did not find a relationship between DNA repair gene polymorphisms and hearing toxicity of cisplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW et al (2012) Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new international society of pediatric oncology boston ototoxicity scale. J Clin Oncol 30(19):2408–2417. https://doi.org/10.1200/JCO.2011.39.1110

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tserga E, Nandwani T, Edvall NK, Bulla J, Patel P, Canlon B et al (2019) The genetic vulnerability to cisplatin ototoxicity: a systematic review. Sci Rep 9(1):3455. https://doi.org/10.1038/s41598-019-40138-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS et al (2014) Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer 61(11):2012–2017

    Article  CAS  Google Scholar 

  4. van As JW, van den Berg H, van Dalen EC (2016) Platinum-induced hearing loss after treatment for childhood cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD010181.pub2

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417–422

    Article  CAS  Google Scholar 

  6. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H et al (2014) Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales—a report from the children’s oncology group. J Clin Oncol 32(6):527–534

    Article  Google Scholar 

  7. Yang JJ, Lim JY, Huang J, Bass J, Wu J, Wang C et al (2013) The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 94(2):252–259

    Article  CAS  Google Scholar 

  8. Paulino AC, Lobo M, Teh BS, Okcu MF, South M, Butler EB et al (2010) Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int J Radiat Oncol Biol Phys 78(5):1445–1450

    Article  CAS  Google Scholar 

  9. Caronia D, Patiño-García A, Milne RL, Zalacain-Díez M, Pita G, Alonso MR et al (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9(5):347–353

    Article  CAS  Google Scholar 

  10. Rademaker-Lakhai JM, Crul M, Zuur L, Baas P, Beijnen JH, Simis YJ et al (2006) Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24:918–924

    Article  CAS  Google Scholar 

  11. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B et al (2017) Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Res 23(13):3325–3333. https://doi.org/10.1158/1078-0432.CCR-16-2809

    Article  CAS  PubMed  Google Scholar 

  12. Brown AL, Lupo PJ, Okcu MF, Lau CC, Rednam S, Scheurer ME (2015) SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med 4(11):1679–1686. https://doi.org/10.1002/cam4.516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Soliman SE, D’Silva CN, Dimaras H, Dzneladze I, Chan H, Gallie BL (2018) Clinical and genetic associations for carboplatin-related ototoxicity in children treated for retinoblastoma: A retrospective noncomparative single-institute experience. Pediatr Blood Cancer 65(5):26931 10.1002/pbc.26931

    Article  Google Scholar 

  14. Choeyprasert W, Sawangpanich R, Lertsukprasert K, Udomsubpayakul U, Songdej D, Unurathapan U et al (2013) Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms. J Pediatr Hematol Oncol 35(4):e138–e143. https://doi.org/10.1097/MPH.0b013e3182707fc5

    Article  CAS  PubMed  Google Scholar 

  15. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J et al (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300

    Article  CAS  Google Scholar 

  16. Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23(34):8588–8596

    Article  Google Scholar 

  17. Chang KW, Chinosomvatana N (2010) Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788–1795

    Article  CAS  Google Scholar 

  18. Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, Merchant TE et al (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30(10):1034–1041

    Article  CAS  Google Scholar 

  19. Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A et al (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41(12):1345–1349. https://doi.org/10.1038/ng.478

    Article  CAS  PubMed  Google Scholar 

  20. Hagleitner MM, Coenen MJ, Patino-Garcia A, de Bont ES, Gonzalez-Neira A, Vos HI et al (2014) Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One 9(12):e115869. https://doi.org/10.1371/journal.pone.0115869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mironovich OL, Bliznetz EA, Garbaruk ES, Belogurova MB, Subora NV, Varfolomeeva SR et al (2018) The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment. Vestn Otorinolaringol 83(4):60–66. https://doi.org/10.17116/otorino201883460

    Article  CAS  PubMed  Google Scholar 

  22. Thiesen S, Yin P, Jorgensen AL, Zhang JE, Manzo V, McEvoy L et al (2017) TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. Pharmacogenet Genomics 27(6):213–222

    Article  CAS  Google Scholar 

  23. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC et al (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10:4939–4943

    Article  CAS  Google Scholar 

  24. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ et al (2005) Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 15:1534–1538

    Article  Google Scholar 

  25. Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M (2018) The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. BMC Med Genet 19(1):112

    Article  Google Scholar 

  26. Wang Z, Xu B, Lin D, Tan W, Leaw S, Hong X et al (2008) XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer 62:99–104. https://doi.org/10.1016/j.lungcan.2008.02.019

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Ege University School of Medicine, Izmir, Turkey

    Caner Turan

  2. Department of Pediatrics, Division of Pediatric Oncology, Ege University School of Medicine, Izmir, Turkey

    Mehmet Kantar

  3. Department of Medical Biology, Beykent University School of Medicine, Istanbul, Turkey

    Çağdaş Aktan & Buket Kosova

  4. Department of Biostatistics and Medical Informatics, Ege University School of Medicine, Izmir, Turkey

    Mehmet Orman

  5. Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey

    Cem Bilgen & Tayfun Kirazlı

Authors
  1. Caner Turan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mehmet Kantar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Çağdaş Aktan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Buket Kosova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehmet Orman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cem Bilgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tayfun Kirazlı
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehmet Kantar.

Ethics declarations

Conflict of interest

The author(s) declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Turan, C., Kantar, M., Aktan, Ç. et al. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1. Cancer Chemother Pharmacol 84, 1333–1338 (2019). https://doi.org/10.1007/s00280-019-03968-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03968-2

Keywords

Search

Navigation